Jilean Beth Fenaux

Title: Jilean Beth Fenaux: Innovator in Immune Regulation

Introduction

Jilean Beth Fenaux is a notable inventor based in San Mateo, CA (US). She has made significant contributions to the field of immunology, particularly through her innovative work on antibodies that target the human CD200R1 receptor protein. With a total of 2 patents, her research focuses on advancing therapeutic methods for diseases related to immune regulation.

Latest Patents

Fenaux's latest patents include the development of Anti-CD200R1 antibodies and methods of use thereof. These patents provide binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to the hu-CD200R1 receptor protein. The antibodies are designed to decrease, inhibit, and fully block immune regulatory effects mediated by hu-CD200R1. Furthermore, the patents outline methods for using these antibodies to treat diseases and conditions that respond to the modulation of immune regulatory functions mediated by CD200 binding to CD200R1.

Career Highlights

Jilean Beth Fenaux is currently employed at 23andMe, Inc., where she continues to apply her expertise in immunology and antibody development. Her work is instrumental in advancing the understanding of immune responses and developing new therapeutic strategies.

Collaborations

Fenaux collaborates with talented individuals in her field, including Yu Chen and Germaine Fuh-Kelly, who contribute to her research endeavors.

Conclusion

Jilean Beth Fenaux is a pioneering inventor whose work on Anti-CD200R1 antibodies represents a significant advancement in the treatment of immune-related diseases. Her contributions to immunology continue to pave the way for innovative therapeutic solutions.